FibroGen, Inc. — Form 10-Q Summary
Filing identity: The supplied filing is for FibroGen, Inc. (Nasdaq: FGEN), not Kyntra Bio, Inc. It covers the quarter and six months ended June 30, 2020; the financial statements are unaudited.
Business context and reporting period
FibroGen is a biopharmaceutical company developing and commercializing therapies for anemia, fibrotic disease and cancer. Roxadustat is approved for CKD anemia in China and for dialysis patients in Japan; U.S. and European applications were under regulatory review. Pamrevlumab was in clinical development for IPF, pancreatic cancer, Duchenne muscular dystrophy and COVID-19.
Key financial metrics
Amounts below are in millions of dollars, except per-share data.
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | $42.9 | $191.6 | $67.3 | $215.4 |
| Operating costs and expenses | $128.0 | $78.7 | $233.5 | $151.5 |
| Operating income (loss) | $(85.1) | $112.8 | $(166.2) | $64.0 |
| Net income (loss) | $(85.3) | $116.0 | $(163.7) | $70.6 |
| Diluted EPS | $(0.95) | $1.26 | $(1.84) | $0.77 |
- Revenue mix, Q2 2020: $19.0 million development and other revenue, $15.7 million net China product revenue and $8.2 million drug-product revenue from Astellas. No license revenue was recorded.
- Expenses: Q2 research and development was $61.4 million, up 18%; selling, general and administrative expense was $63.5 million, up 138%, mainly reflecting China co-promotional costs with AstraZeneca and higher legal expenses. Six-month R&D was $116.3 million and SG&A was $113.1 million.
- Margins: The filing does not present a consolidated gross-margin measure. Cost of goods sold was $3.1 million for the quarter.
- Cash flow: Six-month operating cash flow was positive $90.2 million, versus use of $6.2 million in 2019. It reflected substantial working-capital movements, including milestone billing/receipts and increased accrued co-promotional expenses; it should not be read as earnings-based cash generation. Investing activities provided $209.9 million, primarily from investment maturities and sales.
- Liquidity: At June 30, cash and cash equivalents were $429.3 million and investments were $256.5 million; accounts receivable was $26.5 million. The company reported $712.3 million in cash, investments and receivables combined. Management said these resources were expected to fund anticipated needs for at least 12 months from the filing date.
- Liabilities and capital: Total liabilities were $392.5 million; total equity was $415.1 million. Finance lease liabilities totaled approximately $43.9 million. The filing reports no conventional borrowings in the presented balance-sheet figures. Accumulated deficit was $948.4 million.
Material changes versus prior comparable periods
- Revenue fell 78% in Q2 and 69% for the first half, principally because 2019 included substantial collaboration milestone revenue: $130 million associated with Astellas’ European MAA milestone and $50 million associated with AstraZeneca’s U.S. NDA milestone. These amounts were largely recognized in 2019; the related milestone cash was billed and received in 2020.
- China roxadustat product revenue began in the third quarter of 2019, contributing $15.7 million net revenue in Q2 2020. Astellas drug-product revenue contributed a further $8.2 million.
- Operating expenses rose 63% in Q2 and 54% in the first half. The company cited increased China launch/co-promotion spending, clinical costs including pamrevlumab Phase 3 work and post-approval studies, patent-related legal costs, and drug manufacturing activity.
- The company moved from prior-year profits to losses in both the quarter and first half, driven by lower revenue and higher expenses.
Outlook, risks and unusual items
- Management expected an FDA decision on the roxadustat U.S. NDA by the December 20, 2020 PDUFA goal date; an advisory committee meeting was not planned at that time. Astellas expected a European decision in mid-2021 and a Japan supplemental NDA decision by year-end 2020.
- In China, roxadustat was listed at hospitals representing approximately 45% of the CKD-anemia market opportunity by quarter-end. Management noted that COVID-19 had slowed trial enrollment and affected China sales, particularly in February and March; the pandemic’s future effects were uncertain.
- FibroGen and AstraZeneca amended their China collaboration after quarter-end, effective July 1, 2020, to establish a jointly owned distribution entity and revise commercial expense and manufacturing-cost arrangements. The accounting impact was still under evaluation and expected to be significant from Q3. The company expected accrued long-term co-promotional expenses to decline by approximately $82 million in Q3.
- The company expected continued losses and stated it may need substantial additional funding. It identified clinical/regulatory execution, product safety and efficacy, competition, reimbursement and pricing, manufacturing and supply, collaboration-partner dependence, China operations and COVID-19 as key risks.
- Outstanding non-cancelable contract obligations were $26.2 million. FibroGen reported no material legal proceedings or material accruals for active legal actions. A UK court invalidated several UK patent designations in an April 2020 ruling; FibroGen and Astellas appealed, and the filing said the ruling did not affect roxadustat exclusivity or freedom to operate.
- Management reported disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2020; no material change in internal control over financial reporting was reported for the quarter.
Most important facts for investors to verify
- Confirm the issuer identity: this filing is FibroGen, not Kyntra Bio.
- Track FDA, EMA and Japan regulatory decisions and any resulting changes to timing, labeling or post-approval requirements.
- Assess whether China hospital listings and roxadustat sales grow, and how NRDL pricing, rebates and the new distribution structure affect net revenue and profitability.
- Review the Q3 accounting and cash-flow effects of the AstraZeneca amendment, including the expected approximately $82 million reduction in accrued co-promotional expenses.
- Monitor clinical enrollment and supply-chain effects from COVID-19, as well as the company’s cash consumption and potential need for financing.
- Evaluate the outcome of the UK patent appeal and other intellectual-property challenges; also note that 2019 milestone-driven revenue makes year-over-year comparisons unusually volatile.